Stereotactic Radiotherapy of Targets in the Lung and Liver

Abstract

Hypofractionated stereotactic irradiation of targets in the lung and liver is a locally effective treatment with actuarial local control rates of 76% after 1 year and 61-76% after 2 years without relevant acute toxicity. Severe late toxicity did not occur, if targets close to the mediastinum were avoided.

Factors important for efficacy of stereotactic body radiotherapy of medically inoperable stage I lung cancer. A retrospective analysis of patients treated in the Nordic countries

“…We found a decline in the number of patients with risk for local failure at a time point around 3 years after SBRT. In previous studies using SBRT, the rate of distant metastases was about 20% [29,32,33,38,39], similar to our results of 25% (35/138). Despite extensive pre-treatment staging procedures including PET and CT of the brain, the rate of distant metastases reported during follow-up still remains at 20% [27].…”

Phase II study on stereotactic body radiotherapy of colorectal metastases

“…In a study of SBRT of tumors in lung and liver performed in Wü rzburg, local control was 61% and survival was 43% 2 years after treatment [22]. A variety of primary and secondary tumor types were included into the two German studies and therefore the survival rates cannot directly be compared to those of the present study.…”

CT evaluations of focal liver reactions following stereotactic body radiotherapy for small hepatocellular carcinoma with cirrhosis: relationship between imaging appearance and baseline liver function

“…Compared with 3D conformal radiotherapy (CRT), which delivers a high dose by conventional fractionation, SBRT is advantageous because it allows the delivery of higher doses to a confined area of the liver [22,23]. However, most reports on SBRT concerned patients with metastatic liver tumours who had normal baseline liver functions.…”